Has Brian Abittan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $240,160 in general payments to Brian Abittan, MD across 638 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Brian Abittan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Brian Abittan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Brian Abittan, MD

Dermatology · New York, NYNPI 1902284482

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $218,930 of the $240,160 with a category attached, or 91.2%. Lilly USA, LLC accounts for 61.3% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $152,676, more than ten times the $2,077 reported in 2021. Among dermatology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$240,160in general payments, 2019–2025

Across 638 payments — averaging $376.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$147K
Botanix SB Inc$56K
Galderma Laboratories, L.p.$17K
Sanofi$7K
Pfizer$5K
AbbVie$2K
plus $7K from 18 others

What the payments were for

Consulting fees$6,7093%
Speaking & faculty fees$218,93091%
Travel & lodging$3,5251%
Food & beverage$10,0314%
Education$9650%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	212	$147,331
Botanix SB Inc	50	$56,049
Galderma Laboratories, L.p.	24	$16,677
Sanofi	12	$6,929
Pfizer	33	$4,992
AbbVie	113	$1,612
Amgen	2	$1,225
Dermavant Sciences, Inc.	38	$1,025
E.r. Squibb & Sons, L.L.C.	58	$998
Johnson & Johnson	31	$936
Merz North America, Inc.	3	$579
Arcutis Biotherapeutics, Inc.	22	$392
Regeneron Healthcare Solutions, Inc.	5	$349
Revance Therapeutics, Inc.	4	$240
Novartis	11	$239
LEO Pharma Inc.	6	$147
Journey Medical Corporation	1	$125
Sanofi-aventis U.S. LLC	1	$99
Biofrontera Inc.	4	$76
Sun Pharmaceutical Industries Inc.	2	$47
UCB, Inc.	2	$38
Mayne Pharma Commercial LLC	2	$27
Almirall LLC	1	$25
Organon	1	$5

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OLUMIANT$78,625
EBGLYSS$65,833
SOFDRA$55,578
NEMLUVIO$16,355
DUPIXENT$6,759
LITFULO$4,290
Otezla$1,200
VTAMA$597
XEOMIN$216
Sotyktu$150

How this compares

$240,160 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York →

Medicare billing

Part B allowed, 2024

$102,389

Medicare patients

243

Services billed

1,346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent PenDupilumab	17	$60,274
Pimecrolimus	11	$4,241
Clobetasol Propionate	73	$3,058
Clindamycin Phosphate	44	$2,886
Triamcinolone Acetonide	87	$2,433
Azelaic Acid	18	$2,192
Tacrolimus	15	$1,716
Minoxidil	130	$1,692
Ketoconazole	109	$1,608
Fluocinonide	37	$1,164
Ammonium Lactate	61	$1,115
Tretinoin	26	$922
Finasteride	42	$649
Mupirocin	65	$580
Metronidazole	12	$577

Paid to pharmacies, not to this prescriber.

Other dermatology in New York

Alexandra GolantNew York$3.6M
David CohenNew York$3M
Michael CameronNew York$2.6M
Saakshi KhattriNew York$2.4M
Amy WechslerNew York$2.4M
Joshua ZeichnerNew York$2.1M
Emma GuttmanNew York$1.7M
George HanNew York$1.6M
Amy SpizuocoNew York$1.3M
Andrew AlexisNew York$834K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →